Kin Master Produtos Químicos
↗Passo Fundo, Brazil
Kin Master Produtos Químicos Ltda. is a prominent Brazilian pharmaceutical company specializing in the production of Active Pharmaceutical Ingredients (APIs) derived from bovine and porcine sources. Founded in 1978 and headquartered in Passo Fundo, Rio Grande do Sul, the company has over 45 years of experience in the pharmochemical sector. It is recognized globally for its high-quality production of Heparin, Pancreatin, and other biological extracts.
The company operates three manufacturing sites, including two in Passo Fundo and one in Rondônia. Kin Master is heavily export-oriented, with approximately 90% of its production destined for international markets including the United States, Europe, and Asia. It maintains rigorous quality control standards, complying with major international pharmacopeias (USP, Ph. Eur., BP) and holding Good Manufacturing Practice (GMP) certifications from Brazil's regulatory agency, ANVISA.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$2M-$10M
Founded:1978
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Biological APIs, Animal-derived extracts
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Enseval Putera Megatrading (Indonesia) - Distribution partner, Hipolabor Farmacêutica (Brazil) - Manufacturing partner for finished dosage forms
COMPETITION
Position:Niche Player
Competitors:BioIberica, Aspen Oss, Opocrin, Cristália, Blau Farmacêutica
LEADERSHIP
Key Executives:
Valentina Baigorria - President
LINKS
Website:kinmaster.com.br
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Kin Master Produtos Químicos. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.